1 day Ago By Defense World Staff
Norges Bank bought a new position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 40,000 shares of the company’s stock, valued at approximately $150,000.
Norges Bank owned about 0.09% of Kyverna Therapeutics as of its most recent SEC filing. Several other institutional investors also recently made changes to their positions in KYTX.
FMR LLC acquired a new position in Kyverna Therapeutics during the 3rd quarter valued at approximately $33,000. China Universal Asset Management Co. Ltd.
acquired a new position in shares of Kyverna Therapeutics during the fourth quarter valued at $34,000. Corebridge Financial Inc. grew its position in shares of Kyverna Therapeutics by 42.
3% during the fourth quarter. Corebridge Financial Inc. now owns 12,811 shares of the company’s stock worth $48,000 after acquiring an additional 3,810 shares during the last quarter.
Rhumbline Advisers grew its position in shares of Kyverna Therapeutics by 31.1% during the fourth quarter. Rhumbline Advisers now owns 25,920 shares of the company’s stock worth $97,000 after acquiring an additional 6,153 shares during the last quarter.
Finally, BNP Paribas Financial Markets lifted its position in Kyverna Therapeutics by 2,166.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 27,197 shares of the company’s stock valued at $133,000 after purchasing an additional 25,997 shares during the last quarter.
18.08% of the stock is owned by institutional investors. Kyverna Therapeutics Trading Up 10.
2 %KYTX stock opened at $2.06 on Friday. The firm’s 50-day moving average is $2.
51 and its two-hundred day moving average is $3.78. The company has a market capitalization of $89.
02 million, a price-to-earnings ratio of -0.59 and a beta of 2.57.
Kyverna Therapeutics, Inc. has a 52 week low of $1.79 and a 52 week high of $24.
59. Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.
88) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.01).
On average, equities research analysts predict that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current year.
Analyst Ratings ChangesSeveral research analysts have commented on KYTX shares. HC Wainwright decreased their target price on shares of Kyverna Therapeutics from $6.00 to $4.
00 and set a “neutral” rating for the company in a research report on Thursday, April 3rd. Morgan Stanley reduced their price objective on Kyverna Therapeutics from $40.00 to $20.
00 and set an “overweight” rating for the company in a research report on Tuesday, April 1st. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Kyverna Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $18.
33.Read Our Latest Research Report on KYTXKyverna Therapeutics Company Profile (Free Report)Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
Featured StoriesFive stocks we like better than Kyverna TherapeuticsGrowth Stocks: What They Are, What They Are NotRobinhood Strategies Could Be a Game-Changer for Young InvestorsA Deeper Look at Bid-Ask SpreadsAre These 3 Retail Stocks Oversold or Really in Trouble?What is a Special Dividend?IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead.
